Ikena Oncology, Inc. financial data

Symbol
IKNA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
50 Northern Ave., Boston, MA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.33K % +50.8%
Debt-to-equity 13.2 % -11.5%
Return On Equity -42.8 % -1.88%
Return On Assets -36.2 % +1.04%
Operating Margin -823 % -81.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 48.3M shares +14.1%
Common Stock, Shares, Outstanding 48.3M shares +14.1%
Entity Public Float 179M USD
Common Stock, Value, Issued 48K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 48.3M shares +22.8%
Weighted Average Number of Shares Outstanding, Diluted 48.3M shares +22.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 9.16M USD -41.4%
Research and Development Expense 48.4M USD -25.8%
General and Administrative Expense 25.6M USD +22.4%
Operating Income (Loss) -75.5M USD -12.6%
Nonoperating Income (Expense) 2.16M USD +56.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -13.7M USD +20.1%
Income Tax Expense (Benefit) 62K USD
Net Income (Loss) Attributable to Parent -66.7M USD -6.28%
Earnings Per Share, Basic -1.41 USD/shares +16.6%
Earnings Per Share, Diluted -1.41 USD/shares +16.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 44.3M USD -37.5%
Marketable Securities, Current 101M USD +17%
Cash, Cash Equivalents, and Short-term Investments 176M USD +11.9%
Other Assets, Current 1.15M USD +19.3%
Assets, Current 149M USD -7.05%
Property, Plant and Equipment, Net 772K USD -73.1%
Operating Lease, Right-of-Use Asset 4.78M USD +4.46%
Assets 157M USD -8.31%
Accounts Payable, Current 1.41M USD -20.5%
Employee-related Liabilities, Current 1.4M USD -27.5%
Contract with Customer, Liability, Current 659K USD -94.6%
Liabilities, Current 8.2M USD -31.7%
Contract with Customer, Liability, Noncurrent 2.5M USD -88.8%
Operating Lease, Liability, Noncurrent 5.4M USD +76.6%
Other Liabilities, Noncurrent 1.03M USD
Liabilities 14.6M USD -2.91%
Accumulated Other Comprehensive Income (Loss), Net of Tax -350K USD +23.2%
Retained Earnings (Accumulated Deficit) -312M USD -27.2%
Stockholders' Equity Attributable to Parent 143M USD -8.83%
Liabilities and Equity 157M USD -8.31%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.3M USD +7.48%
Net Cash Provided by (Used in) Financing Activities 495K USD -99.6%
Net Cash Provided by (Used in) Investing Activities -48.7M USD -351%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 48.3M shares +14.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 45.5M USD -36.5%
Deferred Tax Assets, Valuation Allowance 101M USD +68.6%
Deferred Tax Assets, Gross 103M USD +66.1%
Operating Lease, Liability 10.7M USD +88.6%
Depreciation 219K USD -5.2%
Payments to Acquire Property, Plant, and Equipment 152K USD +361%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -66.6M USD -7.21%
Lessee, Operating Lease, Liability, to be Paid 12M USD +86%
Property, Plant and Equipment, Gross 5.07M USD +0.84%
Operating Lease, Liability, Current 3.7M USD +90.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.21M USD +124%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.92M USD +115%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.29M USD +67.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.17M USD +63.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 949K USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 719K USD -12%
Additional Paid in Capital 455M USD +13.1%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 7.03M USD -6.84%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%